Get the Stockscreener App
19.94
0.86%
0.17
Pre-market:
20.11
0.17
+0.85%
Syndax Pharmaceuticals Inc stock is traded at $19.94, with a volume of 1.11M.
It is up +0.86% in the last 24 hours and down -9.69% over the past month.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
See More
Previous Close:
$19.77
Open:
$19.78
24h Volume:
1.11M
Relative Volume:
0.72
Market Cap:
$1.77B
Revenue:
$217.42M
Net Income/Loss:
$-243.25M
P/E Ratio:
-7.1337
EPS:
-2.7952
Net Cash Flow:
$-278.35M
1W Performance:
-1.43%
1M Performance:
-9.69%
6M Performance:
+14.33%
1Y Performance:
+84.46%
1-Day Range:
$19.75
$20.55
1-Week Range:
$19.00
$20.83
52-Week Range:
$8.585
$25.59
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Name
Syndax Pharmaceuticals Inc
Sector
Industry
Phone
781-419-1400
Address
730 THIRD AVENUE, NEW YORK, MA
Compare SNDX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
19.94 | 1.75B | 217.42M | -243.25M | -278.35M | -2.7952 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-16-25 | Resumed | H.C. Wainwright | Buy |
| Sep-10-25 | Resumed | Stifel | Buy |
| Sep-04-25 | Resumed | Guggenheim | Buy |
| Aug-05-25 | Reiterated | BTIG Research | Buy |
| Jul-10-25 | Initiated | Goldman | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| Jun-28-24 | Initiated | Jefferies | Buy |
| Jan-31-24 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Dec-22-23 | Initiated | Mizuho | Buy |
| Oct-25-23 | Initiated | BofA Securities | Buy |
| Oct-11-23 | Initiated | Goldman | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-11-23 | Initiated | Guggenheim | Buy |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Jan-31-23 | Initiated | Stifel | Buy |
| Jan-03-23 | Initiated | JP Morgan | Overweight |
| Jul-28-22 | Resumed | B. Riley Securities | Buy |
| Apr-11-22 | Initiated | H.C. Wainwright | Buy |
| Feb-15-22 | Initiated | Goldman | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| May-25-21 | Initiated | Citigroup | Buy |
| Feb-18-21 | Initiated | B. Riley Securities | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| May-22-20 | Upgrade | Citigroup | Neutral → Buy |
| May-22-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-18-20 | Downgrade | Citigroup | Buy → Neutral |
| May-11-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-13-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-08-19 | Reiterated | H.C. Wainwright | Buy |
| Jan-04-19 | Initiated | Robert W. Baird | Outperform |
| Jan-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Mar-16-17 | Initiated | FBR & Co. | Outperform |
| Mar-02-17 | Initiated | Instinet | Buy |
| Oct-07-16 | Initiated | Guggenheim | Buy |
| Mar-28-16 | Initiated | Citigroup | Buy |
| Mar-28-16 | Initiated | JMP Securities | Mkt Outperform |
| Mar-28-16 | Initiated | Morgan Stanley | Overweight |
View All
Syndax Pharmaceuticals Inc Stock (SNDX) Latest News
Assessing Whether Syndax Pharmaceuticals (SNDX) Looks Undervalued After Recent Share Price Weakness - Yahoo Finance
SNDX Reiterates by HC Wainwright & Co. -- Price Target Maintained at $40 - GuruFocus
H.C. Wainwright Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Assessing Syndax Pharmaceuticals (SNDX) Valuation After New Revuforj Leukemia Data Spurs Investor Interest - Sahm
Syndax Pharmaceuticals to Present Key Revumenib Data at ASCO 2026, Highlighting Post-Transplant Outcomes and Pharmacokinetic Insights - Quiver Quantitative
Leukemia drug revumenib data to headline 4 ASCO 2026 talks - Stock Titan
BofA Securities Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $29 - Moomoo
Syndax Pharmaceuticals’ SWOT analysis: stock gains momentum on strong launch - Investing.com UK
Syndax Announces Participation in Upcoming Investor Conferences - 富途牛牛
Which Is a Better Investment, Syndax Pharmaceuticals, Inc. or Sarepta Therapeutics, Inc. Stock? - AAII
Point72 (SNDX) reports 1,985,547 shares, 2.3% stake in Syndax - Stock Titan
(SNDX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Does Expanded Revuforj Leukemia Data Set Change The Bull Case For Syndax Pharmaceuticals (SNDX)? - Sahm
Why Syndax Pharmaceuticals (SNDX) is One of the Best Small Cap Stocks to Buy for 10x Potential - Insider Monkey
UBS Trims Price Target on Syndax Pharmaceuticals to $37 From $38, Maintains Buy Rating - Moomoo
UBS Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Cuts Target Price to $37 - Moomoo
SNDX Maintained by UBS -- Price Target Lowered to $37.00 - GuruFocus
Syndax (SNDX) Highlights Revuforj Data Ahead of EHA Congress - GuruFocus
Syndax Pharmaceuticals stock (US88906L1052): Analyst upgrade drives 6.6% gain - AD HOC NEWS
Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition - The Manila Times
Syndax Highlights 12 Revuforj® (revumenib) Abstracts - GlobeNewswire
Leukemia drug revumenib lands 12 studies at European Hematology meeting - Stock Titan
TradingKey - TradingKey
Assessing Syndax Pharmaceuticals (SNDX) Valuation After Stronger Revenue And Narrower Losses - simplywall.st
SNDX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Syndax Pharmaceuticals (SNDX): Analyst Ratings Suggest A 92% Upside Potential - DirectorsTalk Interviews
SNDX Stock Price, Quote & Chart | SYNDAX PHARMACEUTICALS INC (NASDAQ:SNDX) - ChartMill
SNDX SEC FilingsSyndax Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Eight new Syndax hires get stock options for 162,100 shares - Stock Titan
MSN Money - MSN
Stifel Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Raises Target Price to $46 - Moomoo
Syndax Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:SNDX) 2026-05-05 - Seeking Alpha
HC Wainwright Has Optimistic Outlook of SNDX Q2 Earnings - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year - simplywall.st
(SNDX) Risk Channels and Responsive Allocation - Stock Traders Daily
Biotech Momentum Builds As Syndax Pharmaceuticals Draws Market Attention - Kalkine Media
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Just Released Its First-Quarter Earnings: Here's What Analysts Think - 富途牛牛
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 6.6% Following Analyst Upgrade - MarketBeat
Stifel raises Syndax Pharmaceuticals stock price target on therapy outlook By Investing.com - Investing.com Canada
Stifel raises Syndax Pharmaceuticals stock price target on therapy outlook - Investing.com
HC Wainwright Has Optimistic Outlook of SNDX FY2030 Earnings - MarketBeat
Syndax Pharmaceuticals (SNDX) Is Down 10.7% After Revenue Surges And Loss Narrows In Q1 2026 - simplywall.st
Syndax Pharmaceuticals (SNDX) Narrows Q1 Loss To US$42.7 Million Challenging Bearish Narratives - Sahm
Net current asset value per share of Syndax Pharmaceuticals Inc – DUS:1T3 - TradingView
Syndax Pharmaceuticals Q1 Loss Narrows, Revenue Rises - Moomoo
Syndax Pharmaceuticals Reports Over $100 Million in Q1 Combined Sales - HarianBasis.co
Analysts Have Conflicting Sentiments on These Healthcare Companies: Centene (CNC) and Syndax Pharmaceuticals (SNDX) - The Globe and Mail
Jefferies Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Cuts Target Price to $37 - Moomoo
Syndax Pharmaceuticals 1Q Loss $42.7M >SNDX - Moomoo
Syndax (SNDX) Narrows Losses as Revuforj and Niktimvo Gain TractionWhat’s Really Shifting? - Yahoo Finance UK
Syndax Pharmaceuticals Inc Stock (SNDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):